Live Breaking News & Updates on ஃப்ட் ஹார்வர்ட் மருத்துவ பள்ளி
Stay updated with breaking news from ஃப்ட் ஹார்வர்ட் மருத்துவ பள்ளி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
May 15, 2021 For immediate post-MI patients, sacubitril/valsartan (Entresto; Novartis) does not significantly decrease the risk of heart failure (HF) or CV death compared with an ACE inhibitor, the PARADISE-MI trial shows. sacubitril/valsartan is superior to an ACE inhibitor in patients who have symptomatic HF with reduced ejection fraction when it comes to reducing both HF events and total mortality, PARADISE-MI fell short by missing its primary endpoint of a 15% reduction in events needed to demonstrate superiority of the angiotensin receptor neprilysin inhibitor (ARNI) over an ACE inhibitor, ramipril, in this acute MI population. Nevertheless, there was a 10% reduction in the sacubitril/valsartan group and positive reports of reduced events from investigators who participated in the large multinational trial. ....
E-Mail IMAGE: A microscopy image of a section of a mouse colon, showing a protective layer of mucus in green that is often disrupted in human inflammatory bowel disease, or IBD. A. view more Credit: Katharine Ng, Tropini Lab, University of British Columbia Just like us, immune cells need fuel to do their jobs. Despite the tight links between human health including our immunity and how our bodies process what we eat, the intersection of immunology and metabolism remains a poorly understood area of human biology. New awards announced today by The Paul G. Allen Frontiers Group, a division of the Allen Institute, aim to improve that understanding by supporting four research projects in the emerging field of immunometabolism. The projects, which are led by 10 new Allen Distinguished Investigators working in teams of two or three lead investigators per award, will explore new avenues of basic biology, health, disease, and technology development, all f ....